ARDELYX, INC.
According to exchange data compiled by Bloomberg and reported by Investing.com, Ardelyx Inc. options activity rose Friday morning to 11,147 contracts, with puts dominating (10,676). The October 16, 2026 $4 put led with 10,004 contracts. Ardelyx shares fell 18.4% to $3.98, and 3-month volatility rose to 74.93%.
Ardelyx (ARDX) shares fell about 16% pre-open after the company reported Q2 2026 results that missed Wall Street on revenue and EPS and cut full-year guidance. Q2 total product revenue was $118.1M, net loss $16.7M (-$0.07/share). Ardelyx lowered 2026 IBSRELA revenue guidance to $350–$370M and withdrew a prior XPHOZAH long-term target.
ARDELYX, INC. (ARDX) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 ardx-20260630xexhibit991.htm EX-99.1 Document Exhibit 99.1 Ardelyx Reports Second Quarter 2026 Financial Results and Provides Business Update Q2 2026 total product revenue of $118.1 million, reflecting 31% growth year-over-year IBSRELA Q2 2026 revenue growth of 33% year
Over the past 7 days, alphai's AI scored 3 news stories mentioning ARDX (ARDELYX, INC.). Coverage has skewed bearish: 1 bullish, 0 neutral, and 2 bearish.
Recent ARDX coverage spans financial news, earnings and corporate actions.
In the last 30 days, ARDX insiders filed 1 SEC Form 4 transaction — no purchases and 1 sale ($211K). The most active reporter was RAAB MICHAEL, President & CEO, with 1 filing. 100% of activity was filed under pre-arranged Rule 10b5-1 plans.
The article links a sharp selloff in ARDX to a surge in put-heavy options activity, suggesting elevated downside hedging and bearish positioning.
Guidance reset tied to payer prior authorization and step edits is the core near-term risk driver for ARDX.
Guidance revision and commercial demand commentary for IBSRELA and XPHOZAH are likely to drive near-term sentiment and valuation expectations.
The Medicare reimbursement appeal loss is a concrete negative catalyst for Xphozah economics, with near-term earnings as the next validation point.
New debt funding and covenant/default terms can change near-term credit risk and financing optionality.
alphai scores every news story that mentions ARDX with an AI model for sentiment and relevance, and aggregates insider trades from ARDELYX, INC.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
According to exchange data compiled by Bloomberg and reported by Investing.com, Ardelyx Inc. options activity rose Friday morning to 11,147 contracts, with puts dominating (10,676). The October 16, 2026 $4 put led with 10,004 contracts. Ardelyx shares fell 18.4% to $3.98, and 3-month volatility rose to 74.93%.
2 min readArdelyx (ARDX) shares fell about 16% pre-open after the company reported Q2 2026 results that missed Wall Street on revenue and EPS and cut full-year guidance. Q2 total product revenue was $118.1M, net loss $16.7M (-$0.07/share). Ardelyx lowered 2026 IBSRELA revenue guidance to $350–$370M and withdrew a prior XPHOZAH long-term target.
4 min readARDELYX, INC. (ARDX) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 ardx-20260630xexhibit991.htm EX-99.1 Document Exhibit 99.1 Ardelyx Reports Second Quarter 2026 Financial Results and Provides Business Update Q2 2026 total product revenue of $118.1 million, reflecting 31% growth year-over-year IBSRELA Q2 2026 revenue growth of 33% year
5 min readInsider Monkey’s “Claude Portfolio” account says Ardelyx (NASDAQ:ARDX) is undervalued versus an earnings turnaround. It cites a 58% rise in Ibsrela sales last quarter, a goal of $1B annual sales by 2029, and consensus EPS moving from breakeven in 2026 to about $0.52 in 2027. ARDX trades near $5.14; risks include delayed profits, dilution, and Medicare reimbursement pressure after an appeal loss for Xphozah.
6 min readARDELYX, INC. (ARDX) filed an SEC Form 8-K — Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. ardx-20260629 0001437402 false 0001437402 2026-06-29 2026-06-29 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported):
3 min readARDELYX, INC. (ARDX) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. ardx-20260616 0001437402 false 0001437402 2026-06-16 2026-06-16 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported):
3 min readLADENBURG THALM/SH SH began coverage of Ardelyx (NASDAQ:ARDX), assigning a “buy” rating and a $16.00 price target, implying 179.43% upside from the stock’s current level. Other firms cited include Wedbush ($19), BTIG ($17), and HC Wainwright (raised to $18). Ardelyx reported Q1 EPS of -$0.15 and revenue of $94.47M.
5 min readThe article cites a 2023 University of Florida study (revised 2026) saying GPT-4 can extract trading signals from US stock news headlines and predict short-term price direction, especially for small caps and negative events. It also lists stocks from “The Claude Portfolio” on X, claiming AI runs real trades via Autopilot. Examples: Inter & Co (INTR) added after a 14.5% drop; Ardelyx (ARDX) cites Q1’26 revenue $70.1m (+58%); Magnite (MGNI) cites Q1 EPS $0.13 vs $0.05 and a $200m buyback.
4 min readA recent SEC Form 144 filing for Ardelyx (NASDAQ: ARDX) indicates that 5,355 restricted stock units (RSUs) vested on May 19, 2026, and are listed as securities to be sold. The filing also detailed prior sales on February 20, 2026, totaling 2,033 shares for approximately $11,886. The report is considered routine, reflecting individual holder transactions rather than a corporate finance action.
2 min readArdelyx Inc. (Nasdaq: ARDX), a biopharmaceutical company, announced its participation in a fireside chat at the Jefferies Global Healthcare Conference 2026. The event is scheduled for June 3 at 9:55 a.m. ET in New York. A live webcast and subsequent replay will be available on the Ardelyx website.
3 min read
